Ordered mesoporous materials obtained by the sol-gel process have a number of promising applications in various fields of high technology between these controlled release of drugs. The goal was to develop polymeric systems via solgel process consisting of mesoporous silica and Indomethacin allowing the controlled release of the drug. The mesoporous silica was obtained by sol-gel method using the surfactant bromide cetyltrimethylammonium (CTAB) as a director of pores, distilled water, hydroxide ammonium (NH 4 OH) and tetraethylorthosilicate (TEOS). For 300 mg of mesoporous silica was used 30 ml of 1 M HCl solution under reflux at 80 ° for 1 hour for activation. After activation of the mesoporous silica held incorporation of indomethacin dissolved in 5.0 ml of ethanol, 1:1 (m / m) (drug: mesoporous silica) for 24 hours. The material was dried at 40 ° C under reduced pressure. The dry mass was used for preparing implants of 200 mg average weight using hydraulic load prenssa with 3 tons for 7 seconds. The implants were within acceptable ranges for the average weight having Relative Standard Deviation (RSD) of less than 2%. The DRX patterns obtained for the mesoporous silica showed peaks at 2 = 2.49 o . The result reports the hexagonal structure of the mesoporous silica. The infrared spectroscopy -FTIR showed the presence region characteristic for mesoporous silica activated functional groups. The infrared spectroscopy -FTIR for the implants had demonstrated zone that the drug is physically dispersed in the mesoporous silica without chemical interactions were detected. The results
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